Does magnetic resonance imaging improve soft tissue sarcoma contouring for radiotherapy?

• Published in: BJR open 2019, Vol.1 (1), p.20180022-20180022
• Main Authors: Vickers, Alexander John, Thiruthaneeswaran, Niluja, Coyle, Catherine, Manoharan, Prakash, Wylie, James, Kershaw, Lucy, Choudhury, Ananya, Mcwilliam, Alan
• Format: Article
• Language: English
• Subjects: Original Research
• ISSN: 2513-9878; 2513-9878
• DOI: 10.1259/bjro.20180022

Soft tissue sarcomas (STS) are a rare, heterogeneous tumour group. Radiotherapy improves local control. CT is used to plan radiotherapy, but has poor soft tissue definition. MRI has superior soft tissue definition. Contour variation amongst oncologists is an important factor in treatment failure. This study is the first to directly compare STS tumour contouring using CT MRI. Planning CT and weighted MR images of eight patients with STS were distributed to four oncologists. Gross tumour volume was contoured on both imaging modalities using in-house software. Images were recontoured 6 weeks later. The mean distance to agreement (DTA), standard deviation of the DTA, dice similarity coefficient (DSC) and contour volume were calculated for each oncologist and compared to a median contour volume. Results for CT and MRI were compared using a pairwise Student's -test. When comparing MRI to CT, tumour volumes were significantly smaller, with a difference of 21.4 cm across all patients ( = 0.008). There was not a statistically significant difference in the mean distance to agreement or dice similarity coefficient, but the standard deviation of the DTA showed a statistically significant improvement ( = 0.04). For intraobserver variation, there was no statistically significant improvement using MRI CT. Oncologists contour smaller tumour volumes using MRI, with reduced interobserver variation. Improving the reliability and consistency of contouring is needed for improved quality assurance. With further experience, the use of MRI in STS radiotherapy planning may reduce variation between oncologists and contribute to improved local control and reduced treatment toxicities.